Enzyme-substrate-inactivator complex formation can impact time-dependent inhibition kinetics
Drug Metabolism and Disposition · 2026-04 · 54 (4) · 100257
DOI: 10.1016/j.dmd.2026.100257 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-04. Verfasst von Jaydeep Yadav und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics, Merck & Co, Inc, Rahway, New Jersey. Electronic address: jaydeep.yadav@merck.…. Hauptthemen laut MEDLINE: Cytochrome P-450 Enzyme Inhibitors, Cytochrome P-450 Enzyme System. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institutes of Health, National Institute of General Medical Sciences.
Abstract (Originalsprache)
In order to predict drug-drug interactions (DDIs), screening and evaluating time-dependent inhibition (TDI) of cytochrome P450 is an important part of the drug discovery process. In vitro experiments are performed for obtaining TDI parameters (inhibitor binding constant, KI, and inactivation rate constant, kinact), which are further used for the prediction of clinical DDI. This work used numerical methods for analysis of in vitro TDI datasets to estimate KI and kinact. Specifically, the impact of enzyme-substrate-inhibitor (ESI) complex formation on the estimation of KI and kinact was evaluated. A total of 13 datasets were evaluated, all of which exhibited non-Michaelis-Menten kinetics, including activation, biphasic inactivation, partial inactivation, and multiple binding kinetics. Datasets were modeled with and without ESI formation. The difference in inactivation efficiency between models with and without ESI ranged from 0.67 to 2.94-fold across all compounds. This resulted in different DDI predictions ranging from moderate to strong DDI predictions for the same compound. These results suggest that in vitro TDI models should incorporate the observed in vitro kinetic complexities to improve confidence in in vivo DDI prediction. SIGNIFICANCE STATEMENT: In vitro time-dependent inhibition (TDI) analysis is often performed assuming that substrate kinetics do not impact the estimates of KI and kinact. By incorporating enzyme-substrate-inhibitor formation in the enzyme kinetic models, activation- and substrate-dependent kinetics can be modeled simultaneously with TDI, thereby providing a more accurate prediction of drug-drug interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics, Merck & Co, Inc, Rahway, New Jersey. Electronic address: jaydeep.yadav@merck.com.
- Department of Drug Metabolism and Pharmacokinetics, Amgen, Thousand Oaks, California.
- Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania.
Förderung
- NIGMS NIH HHS
- National Institutes of Health
- National Institute of General Medical Sciences
Zitieren
APA
Yadav, J., Wahlstrom, J., Korzekwa, K., & Nagar, S. (2026). Enzyme-substrate-inactivator complex formation can impact time-dependent inhibition kinetics. Drug Metabolism and Disposition, 54(4), 100257. https://doi.org/10.1016/j.dmd.2026.100257
Vancouver
Yadav J, Wahlstrom J, Korzekwa K, Nagar S. Enzyme-substrate-inactivator complex formation can impact time-dependent inhibition kinetics. Drug Metabolism and Disposition. 2026;54(4):100257. doi:10.1016/j.dmd.2026.100257
BibTeX
@article{Yadav2026,
author = {Yadav, Jaydeep and Wahlstrom, Jan and Korzekwa, Ken and Nagar, Swati},
title = {Enzyme-substrate-inactivator complex formation can impact time-dependent inhibition kinetics},
journal = {Drug Metabolism and Disposition},
year = {2026},
volume = {54},
number = {4},
pages = {100257},
doi = {10.1016/j.dmd.2026.100257}
}
EUVIMED